Oppenheimer Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price objective raised by Oppenheimer from $63.00 to $65.00 in a research note released on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

Separately, William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $54.20.

Tarsus Pharmaceuticals Trading Down 3.9 %

Shares of Tarsus Pharmaceuticals stock opened at $44.83 on Thursday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 6.99 and a current ratio of 5.42. The company has a fifty day moving average of $37.84 and a 200 day moving average of $32.53. The company has a market capitalization of $1.71 billion, a P/E ratio of -11.77 and a beta of 1.00. Tarsus Pharmaceuticals has a fifty-two week low of $15.60 and a fifty-two week high of $52.99.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Large investors have recently made changes to their positions in the company. Quest Partners LLC bought a new position in Tarsus Pharmaceuticals during the second quarter valued at approximately $61,000. Canada Pension Plan Investment Board purchased a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter worth approximately $114,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after purchasing an additional 1,530 shares in the last quarter. FMR LLC increased its position in Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares during the last quarter. Finally, Dark Forest Capital Management LP purchased a new stake in Tarsus Pharmaceuticals during the second quarter valued at $202,000. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.